Avalo Therapeutics, Inc. (AVTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of AVTX. The 7-day demo opens the 1M and 3M ranges and puts AVTX on your watchlist.
Start 7-day demoLatest AVTX insider trades
About Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
- WAYNE, PA
- 33
- 2015
- XNAS
AVTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 10 | 101,317 | $1.95M |
| Grant or award | 3 | 3,783 | |
| Option exercise | 18 | 195,578 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AVTX insider transactions (Form 4)
1368 Form 4 filings on record, the earliest from Nov 14, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Rita Jain - Director | Grant or award | Stock Option (Right to Buy) | 1,043 | $14.74 | $15K | |
| Jonathan Goldman - Director | Open-market sale | Common Stock | 3,167 | $14.30 | $45K | |
| Jonathan Goldman - Director | Option exercise | Common Stock | 8,200 | $9.88 | $81K | |
| Jonathan Goldman - Director | Open-market sale | Common Stock | 8,200 | $14.35 footnote F1 | $118K | |
| Jonathan Goldman - Director | Option exercise | Stock Option (Right to Buy) | 8,200 | $0.00 | - | |
| ||||||
| Taylor Boyd - Officer | Grant or award | Stock Option (Right to Buy) | 275,000 | $0.00 | - | |
| Kevin Robert Lind - Director | Grant or award | Stock Option (Right to Buy) | 40,200 | $0.00 | - | |
| Rita Jain - Director | Grant or award | Stock Option (Right to Buy) | 1,572 | $0.00 | - | |
| Gilla Kaplan - Director | Grant or award | Stock Option (Right to Buy) | 20,100 | $0.00 | - | |
| Gilla Kaplan - Director | Option exercise | Common Stock | 3,167 | - | - | |
| Gilla Kaplan - Director | Option exercise | Restricted Stock Units | 3,167 | $0.00 | - | |
 June Sherie Almenoff - Director | Open-market purchase | Common Stock | 500 | $12.50 | $6K | |
| June Sherie Almenoff - Director | Open-market purchase | Common Stock | 500 | $13.00 | $7K | |
Recent AVTX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| CHRISTOPHER RYAN SULLIVAN | Officer | 31,031 | $622K | View on EDGAR | |
| CHRISTOPHER RYAN SULLIVAN | Officer | 3,749 |
AVTX insider trading FAQ
What is the latest insider trade for AVTX?
Avalo Therapeutics, Inc. (AVTX) had 11 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for AVTX runs to 68 Form 4 filings, the earliest from 2024-11-14. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AVTX stock?
No insider purchases of AVTX were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling AVTX stock?
10 insider sales of AVTX were filed in the last 90 days, totaling $1.95M.
Where can I see AVTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AVTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Rita Jain view on EDGAR
- - Kevin Robert Lind view on EDGAR
- - Ron M. Philip view on EDGAR
- - Christopher Ryan Sullivan view on EDGAR
- - Christopher Ryan Sullivan view on EDGAR
- - Mittie Doyle view on EDGAR
- - Christopher Ryan Sullivan view on EDGAR
- - Mittie Doyle view on EDGAR
- - Jennifer Riley view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AVTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AVTX with a 7-day demo
- AVTX on your watchlist
- Every AVTX Form 4 filing on record
- Up to 3 months of AVTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
